190 related articles for article (PubMed ID: 25753820)
1. Obeticholic acid and resveratrol in nonalcoholic fatty liver disease: all that is gold does not glitter, not all those who wander are lost.
Musso G
Hepatology; 2015 Jun; 61(6):2104-6. PubMed ID: 25753820
[No Abstract] [Full Text] [Related]
2. NAFLD: obeticholic acid for the treatment of fatty liver disease--NASH no more?
Ray K
Nat Rev Gastroenterol Hepatol; 2015 Jan; 12(1):1. PubMed ID: 25421586
[No Abstract] [Full Text] [Related]
3. Obeticholic acid for the treatment of nonalcoholic steatohepatitis.
Shah RA; Kowdley KV
Expert Rev Gastroenterol Hepatol; 2020 May; 14(5):311-321. PubMed ID: 32241197
[TBL] [Abstract][Full Text] [Related]
4. Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease.
Makri E; Cholongitas E; Tziomalos K
World J Gastroenterol; 2016 Nov; 22(41):9039-9043. PubMed ID: 27895393
[TBL] [Abstract][Full Text] [Related]
5. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis.
Adorini L; Pruzanski M; Shapiro D
Drug Discov Today; 2012 Sep; 17(17-18):988-97. PubMed ID: 22652341
[TBL] [Abstract][Full Text] [Related]
6. Use of farnesoid X receptor agonists to treat nonalcoholic fatty liver disease.
Sanyal AJ
Dig Dis; 2015; 33(3):426-32. PubMed ID: 26045279
[TBL] [Abstract][Full Text] [Related]
7. Obeticholic acid for the treatment of nonalcoholic steatohepatitis: Expectations and concerns.
Polyzos SA; Kountouras J; Mantzoros CS
Metabolism; 2020 Mar; 104():154144. PubMed ID: 31930974
[No Abstract] [Full Text] [Related]
8. Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis.
Venetsanaki V; Karabouta Z; Polyzos SA
Eur J Pharmacol; 2019 Nov; 863():172661. PubMed ID: 31536725
[TBL] [Abstract][Full Text] [Related]
9. The use of obeticholic acid for the management of non-viral liver disease: current clinical practice and future perspectives.
Gitto S; Guarneri V; Sartini A; Andreone P
Expert Rev Gastroenterol Hepatol; 2018 Feb; 12(2):165-171. PubMed ID: 29082798
[TBL] [Abstract][Full Text] [Related]
10. Nuclear receptors: how do they position in non-alcoholic fatty liver disease treatment?
Machado MV; Cortez-Pinto H
Liver Int; 2014 Oct; 34(9):1291-4. PubMed ID: 24766162
[No Abstract] [Full Text] [Related]
11. Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
Gawrieh S; Chalasani N
Clin Liver Dis; 2018 Feb; 22(1):189-199. PubMed ID: 29128056
[TBL] [Abstract][Full Text] [Related]
12. Obeticholic acid: expanding the therapeutic landscape of NASH.
Arrese M; Cabrera D; Barrera F
Ann Hepatol; 2015; 14(3):430-2. PubMed ID: 25864227
[No Abstract] [Full Text] [Related]
13. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease.
Rotman Y; Sanyal AJ
Gut; 2017 Jan; 66(1):180-190. PubMed ID: 27646933
[TBL] [Abstract][Full Text] [Related]
14. Is obeticholic Acid the solution to nonalcoholic steatohepatitis?
Wong VW; Wong GL; Chan FK
Gastroenterology; 2015 Apr; 148(4):851-2. PubMed ID: 25726736
[No Abstract] [Full Text] [Related]
15. Emerging Therapies for Nonalcoholic Fatty Liver Disease.
Hameed B; Terrault N
Clin Liver Dis; 2016 May; 20(2):365-85. PubMed ID: 27063275
[TBL] [Abstract][Full Text] [Related]
16. [Treatment Options in Non-alcoholic Fatty Liver Disease].
Kim W
Korean J Gastroenterol; 2017 Jun; 69(6):353-358. PubMed ID: 28637104
[TBL] [Abstract][Full Text] [Related]
17. Trials of obeticholic acid for non-alcoholic steatohepatitis.
Armstrong MJ; Newsome PN
Lancet; 2015 Jul; 386(9988):28. PubMed ID: 26169862
[No Abstract] [Full Text] [Related]
18. Trials of obeticholic acid for non-alcoholic steatohepatitis.
Musso G; Cassader M; Gambino R
Lancet; 2015 Jul; 386(9988):27. PubMed ID: 26169860
[No Abstract] [Full Text] [Related]
19. Trials of obeticholic acid for non-alcoholic steatohepatitis - Authors' reply.
Neuschwander-Tetri BA; Van Natta ML; Tonascia J; Brunt EM; Kleiner DE
Lancet; 2015 Jul; 386(9988):28-29. PubMed ID: 26169861
[No Abstract] [Full Text] [Related]
20. Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-analysis.
Elgebaly A; Radwan IA; AboElnas MM; Ibrahim HH; Eltoomy MF; Atta AA; Mesalam HA; Sayed AA; Othman AA
J Gastrointestin Liver Dis; 2017 Mar; 26(1):59-67. PubMed ID: 28338115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
